Predictors and Outcomes of Inappropriate Dosing of Direct Oral Anticoagulants in Patients Receiving Transcatheter Aortic Valve Implantation Authors: Danial Amoey, Mohamed Samy, Karim Elbasha, Ahmad Alali, Martin Landt, Arief Kurniadi, Holger Nef, Ralph Tölg, Gert Richardt, Nader Mankerious Published: 2024 ABSTRACT AbstractIntroductionDirect oral anticoagulant (DOAC) dose adjustment is based on age, renal function, and body weight. There is a paucity of data describing the factors associated with the prescription of inappropriate dosage and their impact on clinical outcomes among patients receiving transcatheter aortic valve implantation (TAVI).MethodsIn a single-center study, 432 patients who were on long-term DOAC therapy and underwent TAVI between 2015 and 2022 were included. We analyzed the predictors and outcomes of inappropriate dosing of DOACs; namely apixaban, dabigatran, edoxaban, and rivaroxaban. A composite endpoint, including all-cause mortality, life-threatening/major bleeding, stroke, peripheral thromboembolic complications, or myocardial infarction, was assessed after 1 year.ResultsIn this TAVI cohort, inappropriate DOAC dosing was observed in 20.6% of patients. Inappropriate DOAC dosage was related to female gender (adj. odds ratio [OR] 2.72, 95% confidence interval [CI] 1.64–4.51, p < 0.001) as well as lower estimated glomerular filtration rate (eGFR) (adj. OR 0.99, 95% CI 0.98–1.00, p = 0.019), and to the administration of non-rivaroxaban DOACs (adj. OR 0.28, 95% CI 0.16–0.50, p < 0.001). After 1 year, patients on both appropriate and inappropriate DOAC dosage exhibited comparable rates of the composite endpoint (OR 0.88, 95% CI 0.53–1.46, p = 0.622). Old age (adj. OR 1.05, 95% CI 1.01–1.10, p = 0.018) as well as anemia (adj. OR 0.86, 95% CI 0.75–0.99, p = 0.031) emerged as independent predictors of the composite endpoint.ConclusionsIn this TAVI cohort, female gender and renal insufficiency were associated with inappropriate DOAC dosage, whereas rivaroxaban was linked to appropriate dosing. Inadequate DOAC dosage did not translate into a worse outcome in our TAVI population.Trial RegistrationProspective Segeberg TAVI Registry (ClinicalTrials.gov identifier: NCT03192774).Keywords: New oral anticoagulant (NOAC), Direct oral anticoagulant (DOAC), Transcatheter aortic valve implantation (TAVI), Transcatheter aortic valve replacement (TAVR) Key Summary Points Why carry out this study? There is a paucity of data describing the factors associated with prescription of potentially inappropriate direct oral anticoagulant (DOAC) dosage among patients receiving transcatheter aortic valve implantation (TAVI).We aimed to investigate the potential impact of inappropriate DOAC dosage on clinical outcomes of patients receiving TAVI. What was learned from the study? In this TAVI cohort, female gender and renal insufficiency were associated with inappropriate DOAC dosage, whereas rivaroxaban was linked to appropriate dosing.Inadequate DOAC dosage did not translate into a worse outcome in our TAVI population. Introduction Aortic valve disease is common, and its prevalence is rising worldwide. In 2017, it was estimated that around 12.6 million individuals worldwide were affected by calcific aortic valve disease [1]. Transcatheter aortic valve implantation (TAVI) has emerged as an effective treatment for patients with symptomatic severe aortic stenosis [2]. It is traditionally recommended for older patients who are at high risk or unsuitable candidates for surgical intervention [3]. Patients receiving TAVI are typically older and often have comorbidities such as atrial fibrillation (AF), which necessitates long-term oral anticoagulation (OAC) [3–6]. Direct oral anticoagulants (DOAC) are highly selective direct factor Xa or thrombin inhibitors with oral bioavailability and rapid onset of action [7]. Previous studies have demonstrated the safety and efficacy of DOAC in preventing thromboembolic events in patients with AF [8]. Consequently, current guidelines recommend using DOAC for the anticoagulation of non-valvular AF [9]. The reported prevalence of pre-existing AF in TAVI patients widely ranges from 16% up to 51.1%, while new-onset AF after TAVI is reported in between 1 and 32% of cases [10]. Additionally, DOACs are approved for treating thromboembolism (e.g., pulmonary embolism or deep vein thrombosis) [11–13]. In stratum 2 of the ATLANTIS trial, TAVI patients with no other indication for anticoagulant therapy were enrolled and randomized to the standard dose of apixaban or antiplatelet therapy. Apixaban was not superior to antiplatelet therapy concerning the primary endpoint and was even associated with a higher non-cardiovascular mortality rate. Major, disabling, and life-threatening bleeds were comparable between the two arms [14]. In the same vein, the GALILEO trial demonstrated that rivaroxaban, employed to prevent valve thrombosis without other indications for oral anticoagulation in TAVI patients, was associated with a higher risk of death or thromboembolic complications and increased bleeding compared to an antiplatelet-based strategy [15]. Accordingly, DOACs are recommended in TAVI patients only in the presence of other clear indications for anticoagulation, and in TAVI per se its administration is not advised [16]. Recently, about 36% of patients undergoing TAVI in a nationwide registry had concomitant indications for long-term oral anticoagulation. Furthermore, DOAC was superior to vitamin K antagonists in terms of lower risk for all-cause mortality and a similar rate of life-threatening or major bleeding [17]. DOAC dose adjustment is primarily based on renal function, specifically the glomerular filtration rate (GFR). Each DOAC preparation has its own GFR thresholds which, if exceeded, may require a dose reduction. Other parameters such as age and body weight may also influence the dosage of some DOACs [18]. Generally, inappropriate DOAC dosage may be associated with lower safety and efficacy of DOAC apart from the association with decreased renal function [19]. The impact of inappropriate DOAC dosage in patients undergoing TAVI is unclear. We aim to investigate predictors and outcomes of inappropriate DOAC dosage in a cohort of patients receiving TAVI. Methods Study Design and Patient Population We investigated patients who received TAVI in a single center (Heart Center, Segeberger Kliniken, Bad Segeberg, Germany) between 2015 and 2022, which have been consecutively included in the Prospective Segeberg TAVI Registry (ClinicalTrials.gov identifier: NCT03192774). Written informed consent was obtained from all patients for analysis of their anonymized data. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. The present study was approved by the ethics committee of the Schleswig–Holstein medical syndicate. Reference number: 168–11. A total of 432 patients who underwent TAVI during the observation period and were receiving long-term DOAC treatment at discharge after TAVI implantation were included. Patients were excluded if they were taking DOAC as part of another trial, were on a short-term DOAC regimen, were receiving concomitant dual antiplatelet therapy (DAPT), or had a failed TAVI. All patients were discussed at a local interdisciplinary heart team, where the indication for TAVI was confirmed. Clinical follow-up was obtained either by on-site clinical visits or scripted telephone interviews with the patients or their general practitioners. A 1-year follow-up rate of 100% was achieved. The appropriateness of DOAC doses was checked retrospectively at discharge from the acute inpatient stay or during the rehabilitation stay, based on the initial eGFR and other commonly accepted dose adjustment criteria [18, 20]. The study population was stratified according to the appropriateness of DOAC dose into patients receiving appropriate DOAC dosage and those receiving inappropriate ones. The study flow chart is shown in Fig. 1. Study flow chart. DAPT dual antiplatelet therapy, DOAC direct oral anticoagulant, OAC oral anticoagulation, SAPT single antiplatelet therapy, TAVI transcatheter aortic valve implantation Endpoint Definitions According to the Valve Academic Research Consortium-2 (VARC-2) criteria, life-threatening bleeding is defined as fatal bleeding, bleeding in a critical organ such as the brain, bleeding with pericardial tamponade, bleeding with hemodynamic shock requiring vasopressors, and bleeding with a hemoglobin fall of more than 5 g/dl or transfusion of more than 4 units of packed red blood cells. Major bleeding included bleeding with a hemoglobin fall of more than 3 g/dl, bleeding requiring a transfusion of 2–3 units of packed red blood cells, bleeding that requires hospitalization, permanent damage, or the need for surgery, and does not meet the criteria for life-threatening bleeding. The endpoint of stroke is defined as acute neurological symptoms lasting at least 24 h, neurological symptoms lasting less than 24 h with neuroimaging evidence of ischemic or hemorrhagic stroke without other explanatory cause, or neurological deficit leading to death. Peripheral thromboembolic complications are defined as thromboembolic events not defined by other endpoints. Myocardial infarction is defined as a significant increase in cardiac enzymes, the presence of ischemic symptoms and electrocardiographic changes, arrhythmias, and imaging evidence of myocardial hypoperfusion [21]. A composite endpoint of all-cause mortality, life-threatening/major bleeding, stroke, peripheral thromboembolic complications, or myocardial infarction was investigated at 1 year. Statistical Analysis Categorical variables were summarized as frequencies and percentages, while continuous variables were summarized as mean ± SD or median [25th–75th quartiles], depending on the variable distribution. Dual inter-group comparisons were conducted using Student′s t test or Mann–Whitney U test for continuous variables or in case of triple comparison, using the ANOVA test or Kruskal–Wallis test for continuous variables. The chi-square test was used for categorical variables inter-group comparisons. Fischer’s exact test was performed whenever chi-square test was not feasible due to small observations. Multivariate binary logistic regression analysis (Wald method) was performed and covariates with p ≤ 0.1 in the univariate analysis were included. Data analysis was performed using SPSS V.24.0 (IBM Corp., NY, USA). Results Demographic and Procedural Characteristics Patients who received inappropriate DOAC dosing after TAVI were older (p = 0.026), more frequently females (p < 0.001), had a higher CHA₂DS₂-VASc score (p = 0.043), lower eGFR—Modification of Diet in Renal Disease (MDRD) values (p = 0.014), and lower pre-procedural hemoglobin levels (p = 0.03) than patients who received appropriate dosage. Procedural characteristics were comparable between the study arms. Demographic and procedural characteristics are displayed in Tables 1 and 2. Table 1Patient characteristics and the corresponding comparison between patient groupsDOAC appropriate dose (343 patients)DOAC under dose (59 patients)DOAC over dose (30 patients)p value*DOAC inappropriate dose (89 patients)p valueaAge (years)82.2 ± 5.883.4 ± 4.284.2 ± 4.60.06783.7 ± 4.40.026Females149 (43.4%)37 (62.7%)22 (73.3%) < 0.00159 (66.3%) < 0.001BMI (kg/m2)26.8 [24–30]27.4 [25–31]25.7 [23–29]0.12826.6 [25–30]0.486CHA₂DS₂-VASc score4.6 ± 1.14.8 ± 1.15.0 ± 1.10.0974.9 ± 1.10.043LV ejection fraction (%)57 [47–60]60 [50–55]53 [45–60]0.02557 [50–61]0.332DOAC indication0.5960.677 History of AF or atrial flutter285 (83.1%)48 (81.4%)25 (83.3%)73 (82.0%) Newly diagnosed AF or atrial flutter43 (12.5%)7 (11.9%)4 (13.3%)11 (12.4%) History of PE or DVT6 (1.7%)4 (6.8%)0(0%)4(4.5%) AHRE1 (0.3%)0(0%)0(0%)0(0%) TAVI thrombosis7(2.0%)0(0%)1(3.3%)1(1.1%) Thrombotic aorta1(0.3%)0(0%)0(0%)0(0%)DOAC type < 0.0010.001 Apixaban159 (46.4%)48 (81.4%)11 (36.7%)59 (66.3%) Dabigatran14 (4.1%)4 (6.8%)3 (10.1%)7 (7.9%) Edoxaban21(6.1%)2 (3.4%)3 (10.0%)5 (5.6%) Rivaroxaban149 (43.4%)5 (8.5%)13 (43.3%)18 (20.2%)SAPT160 (46.6%)30 (50.8%)10 (33.3%)0.28140 (44.9%)0.434PCI during TAVI admission77 (22.4%)19 (32.2%)7 (23.3%)0.26726 (29.2%)0.117Diabetes mellitus104 (30.3%)18 (30.5%)8 (26.7%)0.91426 (29.2%)0.475Hypertension310 (90.4%)55 (93.2%)29 (96.7%)0.42684 (94.4%)0.164Dyslipidemia135 (39.4%)26 (44.1%)12 (40.0%)0.79338 (42.7%)0.325Peripheral vascular disease65 (19.0%)9 (15.3%)4 (13.3%)0.62213 (14.6%)0.216COPD38 (11.1%)5 (8.5%)2 (6.7%)0.6537 (7.9%)0.251Plasma creatinine1.1 ± 0.431.1 ± 0.291.2 ± 0.540.1541.1 ± 0.400.639eGFR MDRD (ml/min)64 [48–81]59 [47–72]49 [35–69]0.02759 [41–72]0.014Coronary disease0.8590.923 1 vessel disease69 (20.1%)13 (22.0%)5 (16.7%)18 (20.2%) 2 vessel disease61 (17.8%)11 (18.6%)7 (23.3%)18 (20.2%) 3 vessel disease79 (23.0%)14 (23.7%)4 (13.3%)18 (20.2%) Previous CABG47 (13.7%)8 (13.6%)3 (10.0%)0.84911 (12.4%)0.448 Previous stroke51 (14.9%)6 (10.2%)6 (20.0%)0.43812 (13.5%)0.445 Previous MI41 (12.0%)7 (11.9%)2 (6.7%)0.6849 (10.1%)0.393 Previous PCI109 (31.8%)16 (27.1%)7 (23.3%)0.52023 (25.8%)0.304Thrombocytes pre-TAVI (thousands) (/nl)201 [159–257]196 [154–273]190 [161–254]0.931196 [159–258]0.843Hemoglobin pre-TAVI (g/dl)12.1 ± 1.711.4 ± 1.412.1 ± 1.70.01711.6 ± 1.40.030Logistic EuroSCORE (%)13.0 [8–21]11 [7–18]11 [8–22]0.42011 [8–20]0.403EuroSCORE II (%)3 [2–6]3 [2–5]3 [2–5]0.8193 [2–5]0.659STS Score (%)3 [2–6]4 [3–5]5 [4–8]0.0084 [3–6]0.060PPG pre-TAVI (mmHg)58 [44–74]68 [51–80]48 [39–62]0.00658 [44–74]0.559MPG pre-TAVI (mmHg)37 [27–48]41 [31–52]30 [21–40]0.00738 [27–50]0.963AVA (cm2) TTE0.7 [0.6–0.9]0.7 [0.6–0.8]0.6 [0.6–0.9]0.4610.7 [0.6–0.8]0.327Data are shown as number (percentage), mean ± standard deviation, or median and interquartile rangeAF atrial fibrillation, AHRE atrial high rate episodes, AVA aortic valve area, BMI body mass index, CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, DOAC direct oral anticoagulant, DVT deep vein thrombosis, eGFR MDRD estimated glomerular filtration rate Modification of Diet in Renal Disease Study, LV left ventricular, MI myocardial infarction, MPG mean pressure gradient, PCI percutaneous coronary intervention, PE pulmonary embolism, PPG peak pressure gradient, SAPT single antiplatelet therapy, STS-Score The Society Thoracic of Surgeons score, TAVI transcatheter aortic valve implantation, TTE transthoracic echocardiogram*p value of appropriate, under- and overdosing comparisonap value of appropriate and inappropriate dosing comparison Patient characteristics and the corresponding comparison between patient groups Data are shown as number (percentage), mean ± standard deviation, or median and interquartile range AF atrial fibrillation, AHRE atrial high rate episodes, AVA aortic valve area, BMI body mass index, CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, DOAC direct oral anticoagulant, DVT deep vein thrombosis, eGFR MDRD estimated glomerular filtration rate Modification of Diet in Renal Disease Study, LV left ventricular, MI myocardial infarction, MPG mean pressure gradient, PCI percutaneous coronary intervention, PE pulmonary embolism, PPG peak pressure gradient, SAPT single antiplatelet therapy, STS-Score The Society Thoracic of Surgeons score, TAVI transcatheter aortic valve implantation, TTE transthoracic echocardiogram *p value of appropriate, under- and overdosing comparison ap value of appropriate and inappropriate dosing comparison Table 2Procedural characteristicsDOAC appropriate dose (343 patients)DOAC under dose (59 patients)DOAC over dose (30 patients)p value*DOAC inappropriate dose (89 patients)p valueaDevice type0.7810.410 CoreValve™ Evolut Pro/Pro plus/R™178 (51.9%)39 (66.1%)17 (56.7%)56 (62.9%) Edwards SAPIEN XT/3/3 ultra™128 (37.3%)16 (27.1%)9 (30%)25 (28.1%) Edwards Centera™2 (0.6%)0 (0%)0 (0%)0 (0%) Acurate neo/neo2™19 (5.5%)3 (5.1%)3 (10%)6 (6.7%) Lotus/Lotus Edge™15(4.4%)1 (1.7%)1 (3.3%)2 (2.2%) Allegra™1 (0.3%)0 (0%)0 (0%)0 (0%)Mean prosthesis size (mm)29 [26–29]29 [27–29]29 [26–29]0.21729 [26–29]0.203Data are shown as number (percentage) or mean ± standard deviationDOAC direct oral anticoagulant*p value of appropriate, under- and overdosing comparisonap value of appropriate and inappropriate dosing comparison Procedural characteristics Data are shown as number (percentage) or mean ± standard deviation DOAC direct oral anticoagulant *p value of appropriate, under- and overdosing comparison ap value of appropriate and inappropriate dosing comparison Adverse Events after 1 year After 1 year, patients on appropriate DOAC dosage at discharge exhibited comparable rates of the composite endpoint compared to those on inappropriate DOAC dosage (odds ratio [OR] 0.88, 95% CI 0.53–1.46, p = 0.622), driven by comparable rates of all-cause mortality (12.8% vs. 7.9%, p value = 0.268), life-threatening/major bleeding (12.8% vs. 15.7%, p value = 0.487), stroke (5.5% vs. 9.0%, p value = 0.226), and myocardial infarction (1.5% vs. 2.7%, p value = 0.637). However, patients who received inappropriate DOAC dosage suffered more peripheral thromboembolic complications (0% vs. 3.4%, p value = 0.009). Paradoxically, this was driven by patients in the overdose group. Adverse events after 1-year follow-up are shown in Table 3. Table 3Rates of adverse events after 1 yearDOAC appropriate dose (343 patients)DOAC under dose (59 patients)DOAC over dose (30 patients)p value*DOAC inappropriate dose (89 patients)p valueaAll-cause death44 (12.8%)3 (5.1%)4 (13.3%)0.2267 (7.9%)0.268Life-threatening bleeding or major bleeding44 (12.8%)9 (15.3%)5 (16.7%)0.76114 (15.7%)0.487Stroke (all ischemic)19 (5.5%)4 (6.8%)4 (13.3%)0.2358 (9.0%)0.226Peripheral thromboembolic complication0 (0%)1 (1.7%)2 (6.7%) < 0.0013 (3.4%)0.009MI5 (1.5%)0 (0%)2 (6.7%)0.0542 (2.7%)0.637Composite endpoint95 (27.7%)13 (22.0%)10 (33.3%)0.49623 (25.8%)0.790DOAC direct oral anticoagulant, MI myocardial infarction, TAVI transcatheter aortic valve implantation*p value of appropriate, under- and overdosing comparisonap value of appropriate and inappropriate dosing comparisonData are shown as number (percentage) or mean ± standard deviation Rates of adverse events after 1 year DOAC direct oral anticoagulant, MI myocardial infarction, TAVI transcatheter aortic valve implantation *p value of appropriate, under- and overdosing comparison ap value of appropriate and inappropriate dosing comparison Data are shown as number (percentage) or mean ± standard deviation After adjustment for potential confounders, age (adj. OR 1.05, 95% CI 1.01–1.10, p = 0.018) and lower hemoglobin levels (adj. OR 0.86, 95% CI 0.75–0.99, p = 0.031) were found to be independent predictors of the composite endpoint. Independent predictors of composite endpoint are shown in Table 4. Table 4Independent predictors of composite endpointUnivariateMultivariateOdds ratio95% confidence intervalp valueOdds ratio95% confidence intervalp valueDOAC inappropriate dose0.880.53–1.460.622DOAC underdose0.740.38–1.430.366DOAC overdose1.310.59–2.890.511Age1.061.02–1.110.0041.051.01–1.100.018Female gender1.541.00–2.350.0481.320.85–2.050.214BMI1.000.96–1.040.984LV ejection fraction (%)1.010.99–1.020.545CHA₂DS₂-VASc score0.970.80–1.180.770Apixaban0.930.61–1.420.738Dabigatran0.820.30–2.300.712Edoxaban1.440.62–3.330.391Rivaroxaban1.020.66–1.570.932SAPT1.170.77–1.790.466Diabetes mellitus0.570.35–0.940.0260.610.37–1.010.053Hypertension0.620.31–1.230.171Dyslipidemia0.990.64–1.520.955COPD0.740.35–1.540.419eGFR MDRD (ml/min)0.990.99–1.000.155Hemoglobin pre-TAVI (g/dl)0.860.75–0.980.0210.860.75–0.990.031AVA (cm2) TTE0.740.37–1.460.379AVA aortic valve area, BMI body mass index, COPD chronic obstructive pulmonary disease, DOAC direct oral anticoagulant, eGFR MDRD estimated glomerular filtration rate Modification of Diet in Renal Disease Study, LV left ventricular, SAPT single antiplatelet therapy, TAVI transcatheter aortic valve implantation, TTE transthoracic echocardiogram Independent predictors of composite endpoint AVA aortic valve area, BMI body mass index, COPD chronic obstructive pulmonary disease, DOAC direct oral anticoagulant, eGFR MDRD estimated glomerular filtration rate Modification of Diet in Renal Disease Study, LV left ventricular, SAPT single antiplatelet therapy, TAVI transcatheter aortic valve implantation, TTE transthoracic echocardiogram Predictors of Inappropriate DOAC Dosing In a multivariate regression analysis, the inappropriate dosing was associated with the female gender (adj. OR 2.72, 95% CI 1.64–4.51, p < 0.001) and lower eGFR MDRD (adj. OR 0.99, 95% CI 0.98–1.00, p = 0.019). Inappropriate dosing was also associated with the use of a non-rivaroxaban DOAC (adj. OR 0.28, 95% CI 0.16–0.50, p < 0.001). Demographic and clinical elements in relation to potentially inappropriate dosing of DOACs are shown in Table 5. Table 5Demographic and clinical elements related to potential inappropriate DOAC dosingUnivariateMultivariateOdds ratio95% confidence intervalp valueOdds ratio95% confidence intervalp valueAge1.051.01–1.100.0271.030.98–1.080.210Female gender2.561.57–4.17 < 0.0012.721.64–4.51 < 0.001BMI1.030.99–1.080.140Previous stroke1.680.71–3.990.235PCI during TAVI admission1.430.85–2400.183CHA₂DS₂-VASc score1.251.01–1.550.0441.010.78–1.300.955SAPT0.930.58–1.490.774eGFR MDRD (ml/min)0.990.98–1.000.0150.990.98–1.000.019Apixaban2.281.40–3.710.0011.020.48–2.170.953Dabigatran2.010.78–5.130.146Edoxaban0.910.33–2.490.859Rivaroxaban0.330.19–0.58 < 0.0010.280.16–0.50 < 0.001BMI body mass index, DOAC direct oral anticoagulant, eGFR MDRD estimated glomerular filtration rate Modification of Diet in Renal Disease Study, PCI percutaneous coronary intervention, SAPT single antiplatelet therapy, TAVI transcatheter aortic valve implantation Demographic and clinical elements related to potential inappropriate DOAC dosing BMI body mass index, DOAC direct oral anticoagulant, eGFR MDRD estimated glomerular filtration rate Modification of Diet in Renal Disease Study, PCI percutaneous coronary intervention, SAPT single antiplatelet therapy, TAVI transcatheter aortic valve implantation Discussion The principal findings of this study can be summarized as follows: In this TAVI cohort, over 20% of patients treated with a DOAC received an inappropriate dose. In this TAVI cohort, over 20% of patients treated with a DOAC received an inappropriate dose. Inappropriate DOAC dosing was linked to female patients and to patients with lower GFR, notably; treatment with rivaroxaban was associated with more appropriate dosing. Inappropriate DOAC dosing was linked to female patients and to patients with lower GFR, notably; treatment with rivaroxaban was associated with more appropriate dosing. Patients on both appropriate and inappropriate DOAC dosage exhibited comparable rates of the composite endpoint after 1 year. Patients on both appropriate and inappropriate DOAC dosage exhibited comparable rates of the composite endpoint after 1 year. Age and low hemoglobin levels have been shown to be independent predictors of the composite endpoint. Age and low hemoglobin levels have been shown to be independent predictors of the composite endpoint. To the best of our knowledge, this study is the first to investigate the prevalence and impact of incorrect DOAC dosing on 1-year outcomes in a large TAVI registry. Our analysis revealed a 20.6% risk of inappropriate dosing of DOACs, with 13.7% of patients being underdosed and 6.9% being overdosed. This is similar to the SAGE-AF study targeting the geriatric AF population, in which 23% experienced inappropriate DOAC dosing [22]. Moreover, a recent cross-sectional multicenter analysis targeting elderly patients with AF receiving DOACs reported a 24.0% prevalence of inappropriate dosing, with 14.4% being underdosed and 9.6% being overdosed [23]. In a recent analysis, patients who received DOACs after TAVI without additional antiplatelet therapy exhibited a mortality rate of 7.8%, a major bleeding rate of 1.9%, and an ischemic stroke rate of 2.6% at 6 months [24]. Our analysis, with a longer follow-up period, showed higher event rates, possibly due to the extended observation period. It is notable that the use of single antiplatelet therapy (SAPT) was permitted in our study. Additionally, a meta-analysis examining inappropriate DOAC dosing in patients with AF found that DOAC underdosing is linked to higher mortality rates, whereas overdosing with increases major bleedings [25]. Despite observing more peripheral thromboembolic complications in patients with inappropriate dosing in our analysis, we found no significant difference in the composite endpoint between appropriate and inappropriate dosing groups, most likely due to low event rate and relatively small cohort, necessitating further validation in larger studies. In our analysis, age and lower pre-procedural hemoglobin levels emerged as independent predictors of the composite endpoint post-TAVI. In the same vein, a previous report demonstrated a correlation between anemia, blood transfusion, and higher 1-year mortality rates following TAVI [26]. This association might originate from the immunosuppressive, pro-inflammatory, and pro-thrombotic effects of blood transfusions, which have also been linked to complications such as acute kidney injury and multi-organ failure [27–29]. Conversely, maintaining normal hemoglobin levels appears to offer protective benefits. Impaired renal function and female gender were previously identified as established predictors of inappropriate DOAC dosing post-TAVI, possibly due to the higher incidence of chronic kidney disease in women, necessitating dose adjustments and thereby increasing the risk of dosage errors [22, 30–32]. Recent research findings indicate a lower risk of stroke, systemic embolism, and major bleeding associated with apixaban compared to other anticoagulants like warfarin, rivaroxaban, and dabigatran in patients with AF and non-dialysis-dependent chronic kidney disease (CKD) [33]. Moreover, further analysis revealed that apixaban demonstrated the lowest risk of inappropriate dosing in stroke patients, possibly due to its more flexible dose adjustment criteria compared to other DOACs [31]. Conversely, the current analysis identified rivaroxaban association with appropriate dosing, likely influenced by our population characteristics, with probable better compliance related to a daily single dose of rivaroxaban. Future perspectives in DOAC dose adjustment methods may include utilizing parameters like cystatin C for more accurate assessment of renal function, direct measurement of DOAC plasma concentrations, or employing specialized coagulation tests to assess coagulation effects objectively [34–37]. However, the long-term preference for DOAC therapy as the primary anticoagulant remains uncertain, as phase 2 studies on factor XI inhibitors have shown promising results with lower bleeding rates compared to DOACs in anticoagulation contexts [38]. Limitations Our study has the following limitations. First, the single-center, retrospective, non-randomized designs, in which operator bias and unmeasured confounders may preclude definitive conclusions. Second, we used the eGFR-MDRD formula rather than the eGFR-CKD-Epi formula recommended by nephrology guidelines, because it is the method of calculation adopted by the local laboratory [39]. Third, it should be acknowledged that the renal function parameters in our cohort were determined on admission to the hospital without the influence of interventional procedures involving contrast agents. Based on other studies, we assumed that patients would achieve similar or better eGFR values at discharge and during the course of their treatment than at admission, also due to the post-procedural improvement in renal perfusion after TAVI [40]. Fourth, our study did not consider liver dysfunction and drug interactions which may affect DOAC plasma concentrations. Conclusions In this TAVI cohort, female gender and renal insufficiency were associated with inappropriate DOAC dosage, whereas rivaroxaban was linked to appropriate dosing. Inadequate DOAC dosage did not translate into a worse outcome in our TAVI population. Authors' Contributions All authors contributed to the study’s conception and design. Material preparation, data collection, and analysis were performed by Danial Amoey, Mohamed Samy, Karim Elbasha, Ahmad Alali, and Martin Landt MD. The first draft of the manuscript was written by Arief Kurniadi, Holger Nef, Ralph Tölg, Gert Richardt, and Nader Mankerious. All authors commented on previous versions of the manuscript. Danial Amoey, Mohamed Samy MD, Karim Elbasha, Ahmad Alali, Martin Landt, Arief Kurniadi, Holger Nef, Ralph Tölg, Gert Richardt, and Nader Mankerious read and approved the final manuscript. Funding No funding or sponsorship was received for this study or publication of this article. Data Availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Statistical analysis was conducted using SPSS V.24.0 (IBM Corp., NY, USA). Declarations Conflict of Interest Nader Mankerious received speaker honoraria from BIOTRONIK and Boston Scientific. Gert Richardt received an institutional research grant from Boston Scientific. Gert Richardt is an Editorial Board member of Cardiology and Therapy. Gert Richardt was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Danial Amoey, Mohamed Samy, Karim Elbasha, Ahmad Alali, Martin Landt, Arief Kurniadi, Holger Nef, and Ralph Tölg have no conflicts of interest to declare. Ethical Approval Written informed consent was obtained from all patients for analysis of their anonymized data. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. The present study was approved by the ethics committee of Schleswig–Holstein medical syndicate. Reference number: 168–11. Footnotes Prior Presentation This manuscript is based on work that was previously presented at the EURO PCR 2024 Conference in Paris. References Associated Data Data Availability Statement The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Statistical analysis was conducted using SPSS V.24.0 (IBM Corp., NY, USA).